.
MergerLinks Header Logo

Announced

Completed

SoftBank Group, Heritage Provider Network, Irving Investors and Highside Capital Management led a $201m Series C round in InterVenn Biosciences.

Financials

Edit Data
Transaction Value£144m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Completed

Friendly

United States

Acquisition

Private Equity

Private

biotechnology company

Venture Capital

Cross Border

Biotechnology

Minority

Synopsis

Edit

SoftBank Group, Heritage Provider Network, Irving Investors and Highside Capital Management led a $201m Series C round in InterVenn Biosciences, a biotechnology company, with participation from Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The proceeds from the financing will be used to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US